BioPharmSignal logoBioPharmSignal

Biotech News

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTC Therapeutics, Inc. (PTCT)PTC Therapeutics, Inc.Commercial

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety

Related news

PTCTPTC Therapeutics, Inc.2026-09-21 20:30 EST

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

RCKTRocket Pharmaceuticals2026-10-06 20:12 EST

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

ETONEton Pharmaceuticals2026-09-28 10:50 EST

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

RCKTRocket Pharmaceuticals2026-09-03 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

MNPRMonopar2026-07-20 12:00 EST

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

PTCTPTC Therapeutics, Inc.2026-08-24 12:00 EST

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

ABEOAbeona Therapeutics2026-07-21 11:30 EST

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

ABEOAbeona Therapeutics2026-09-16 11:30 EST

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

PHARPharming Group2026-08-13 05:00 EST

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

BIIBBiogen2026-06-29 10:59 EST

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

View all latest news

PTC Therapeutics, Inc.

Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases. Commercial Portfolio Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise....

Recent company news

PTCTPTC Therapeutics, Inc.2026-10-15 12:00 EST

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

PTCTPTC Therapeutics, Inc.2026-09-25 20:30 EST

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTCTPTC Therapeutics, Inc.2026-09-21 20:30 EST

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PTCTPTC Therapeutics, Inc.2026-08-27 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-08-24 12:00 EST

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

Stock data

Close
62.62 USD
Market cap
5.66B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States